
“The Food and Drug Administration left medicines on the market for years after discovering they were approved based on fraudulent studies by Cetero Research, which did testing for drug companies worldwide. Turns out that wasn’t an anomaly: The agency’s slow, secretive response in the Cetero case mirrors how it handled an earlier instance of scientific misconduct at another contract research organization, MDS Pharma Services. Just as in the Cetero case, the agency declined to make public a list of the 217 generic drugs, both on the shelves and awaiting approval, that it said could be affected by MDS’ potentially faulty research.”
Related posts:
Dashcam catches cops in unbelievable lies in man’s false arrest
Texas jailer must face trial after video caught him raping 15-year-old
Getting Out Is Hard; Getting Back In Is Harder
Mining your iPhone: 'More gold in 1 pound of electronics than 1 pound of gold ore'
Extensive Syrian Timeline Exposes Buildup to False Flag
Why Amazon’s Fighting So Hard for a CIA Cloud Contract
And the Winner of Bush’s Iraq War Is . . . Iran!
Anti-drone protests kick off in San Diego
1794 Silver Dollar sets 10 Million + World Record at Stacks Bowers Auction in NY
Airlines Are Giving Your Face to Homeland Security
Is Actor Johnny Revilla Stateless?
U.S. Ready to Offer Mercenaries $10 Billion for a Drug-War Air Force
Even who we’re in a drone war with is classified
New York Fed Cancels Tours of Its Gold Vaults
First France, Now Brazil Unveils Internet Censorship To Combat “Fake News”